| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Ozagrel methyl ester does not have a defined biological target as it is a prodrug/impurity. The parent drug ozagrel is a selective inhibitor of thromboxane A2 synthase (TXA2 synthase, EC 5.3.99.5), an enzyme responsible for the production of thromboxane A2, a potent vasoconstrictor and platelet aggregator. Ozagrel is used clinically to treat ischemic stroke and asthma. Upon hydrolysis by non-specific esterases, ozagrel methyl ester releases the active ozagrel. The methyl ester prodrug approach is intended to increase the molecule's lipophilicity for better GI absorption.
|
|---|---|
| ln Vitro |
Ozagrel methyl ester itself does not have significant in vitro activity until hydrolyzed to its active form, ozagrel. In vitro, ozagrel inhibits TXA2 synthase with an IC50 of approximately 0.5-2 microM. The methyl ester can be used to study esterase-mediated drug activation. It is also used as an analytical standard to identify and quantify impurities in ozagrel drug substance. No specific cell-based activity data for the methyl ester are reported.
|
| ln Vivo |
No in vivo activity data are available for ozagrel methyl ester as a standalone impurity. However, the parent drug ozagrel is clinically used as an antithrombotic agent. Ozagrel methyl ester, if administered, would be expected to be rapidly hydrolyzed to ozagrel by esterases in the GI tract and plasma, then exhibit antithrombotic activity. It is not used for efficacy studies. For research use only.
|
| Enzyme Assay |
Not applicable. Ozagrel methyl ester is a pharmaceutical impurity and analytical standard. For non-cellular characterization, a standard HPLC method is used: dissolve the compound in methanol or acetonitrile to 1 mg/mL. Inject onto a C18 column (250×4.6 mm, 5 microm). Mobile phase: 0.1% formic acid in water (A) and acetonitrile (B). Isocratic: 50% B. Flow rate: 1.0 mL/min, UV detection at 254 nm. Retention time is approximately 8-10 min. For LC-MS/MS, positive ESI mode, m/z 243 [M+H]+. Melting point: 113-117degC. Purity >98% (GC). No enzyme assays.
|
| Cell Assay |
Not applicable. Ozagrel methyl ester is not used in cell-based biological assays. It is a chemical reference standard for analytical quality control. For cell culture studies, the active ozagrel would be used. For research use only.
|
| Animal Protocol |
Not applicable. Ozagrel methyl ester is not used for in vivo animal studies. It is a reference standard for chemical analysis. No animal dosing or efficacy studies are performed with this compound. For research use only.
|
| ADME/Pharmacokinetics |
Not applicable. Ozagrel methyl ester is a pharmaceutical impurity, not a drug candidate. Its pharmacokinetic properties are not characterized. The parent drug ozagrel has a half-life (t½) of approximately 0.5-1.5 h in humans, low oral bioavailability due to first-pass metabolism, and is extensively metabolized. The methyl ester, if used as a prodrug, is designed to be rapidly hydrolyzed. For storage, powder at -20degC for up to 3 years, protected from light and moisture. Solubility: DMSO, methanol, ethanol. Appearance: solid.
|
| Toxicity/Toxicokinetics |
No toxicity data are available for ozagrel methyl ester as a pure compound. In pharmaceutical manufacturing, the allowable limit of this impurity is controlled (typically ≤0.1-0.5%). Standard laboratory safety precautions for handling chemical reference standards should be followed: avoid inhalation, ingestion, skin/eye contact; use PPE (gloves, lab coat, safety goggles); work in a fume hood. For research use only-not for human use.
|
| Additional Infomation |
CAS: 866157-50-8. Molecular formula: C14H14N2O2, molecular weight: 242.27. IUPAC name: methyl (E)-3-(4-((1H-imidazol-1-yl)methyl)phenyl)acrylate. Also known as Ozagrel Impurity G, ozagrel methylester. Purity: typically >98% (GC). Melting point: 113-117degC. Appearance: solid. Storage: -20degC. Use: pharmaceutical reference standard, impurity profiling. Not for human use. For research only.
|
| Molecular Formula |
C14H14N2O2
|
|---|---|
| Molecular Weight |
242.27
|
| CAS # |
866157-50-8
|
| Related CAS # |
Ozagrel methyl ester
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1276 mL | 20.6381 mL | 41.2763 mL | |
| 5 mM | 0.8255 mL | 4.1276 mL | 8.2553 mL | |
| 10 mM | 0.4128 mL | 2.0638 mL | 4.1276 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
